News | Radiation Therapy | January 05, 2017

Varian Launches New Online Educational Resource for Healthcare Professionals

Site provides video and audio symposia on the management of cancers and other conditions, emphasizing radiotherapy applications

Varian, radiotherapy, online educational resource, cancer

January 5, 2017 — Varian Medical Systems recently announced the launch of a new website for the exchange of clinical information, scientific research and expert opinion around the management of cancers and other conditions, with an emphasis on applications utilizing radiotherapy

At launch the site is offering video- and audio-taped symposia that Varian has supported or sponsored in the recent past, including a recent self-assessment continuing medical education (SA-CME) accredited webinar, and a selection of bibliographies organized by disease site. In the future the site will house additional resources including webinars with educational credits, information about sponsored/translational research and clinical trials, case studies, and FAQs for the medical professional. 

For more information: www.medicalaffairs.varian.com

Related Content

targeted radiosurgery, stereotactic radiosurgery, whole-brain radiation, brain tumor metastases, Cureus, University of Missouri School of Medicine study
News | Radiation Therapy | February 16, 2017
University of Missouri (MU) School of Medicine researchers compared two common postsurgical therapies for metastatic...
ASTRO guideline, bone metastases, pallliative radiation therapy, gold standard
News | Radiation Therapy | February 14, 2017
February 14, 2017 — The American Society for Radiation Oncology (ASTRO) recently published an updated clinical guidel
Accuray, Radixact treatment delivery system, TomoTherapy, Shonin approval, Japan
News | Radiation Therapy | February 13, 2017
February 13, 2017 — Accuray Inc.
state of the proton therapy market entering 2017, proton therapy, radiation therapy, Robust Insight survey
News | Proton Therapy | February 10, 2017
Independent market research consultancy Robust Insight recently conveyed a survey commissioned by IBA on the state of...
EGFR mutant lung cancer, brain metastases, order of treatment, radiation therapy, EGFR-directed drugs, Journal of Clinical Oncology study
News | Lung Cancer | February 09, 2017
February 9, 2017 — A study published in the...
IBA, Dolphin Online Ready Patient QA and Monitoring solution, radiotherapy, North West Cancer Centre, Londonderry, Northern Ireland, first in U.K.
News | Radiation Therapy | February 07, 2017
IBA (Ion Beam Applications S.A.) recently announced the first clinical implementation of its Dolphin Online Ready...
Institut Curie, Onxeo, radiotherapy, immunotherapy, DNA repair inhibitors, AsiDNA, DBait
News | Radiation Therapy | February 06, 2017
Onxeo S.A. and the Institut Curie launched a series of studies on World Cancer Day (Feb. 4) aimed at investigating the...
radiotargeted therapy, SST2 antagonists, combat cancer, neuroendocrine tumors, NETs, Journal of Nuclear Medicine study

Comparative receptor autoradiography in various cancer types (A = HE staining) with I-125-JR11 (B+C) and I-125-Tyr3-octreotide (D+E). B and D are the respective total binding, C and E the respective non-specific binding. Bars = 1 mm.

I: Breast cancer. II: Renal cell cancer. III: Medullary thyroid cancer. IV: Non-Hodgkin lymphoma. V: Colon cancer. In cancers I-V, the sections were incubated with 30’000 cpm/100 μl of antagonist or agonist. Cancers I-IV show a much higher density of sst2 with the antagonist. The colon cancer V is negative. VI: Ileal NET, incubated with 10’000 cpm/100 μl of antagonist or agonist. Credit: Jean Claude Reubi, Institute of Pathology, University of Berne, Berne, Switzerland. 

News | Radiation Therapy | February 06, 2017
A study published in the February issue of The Journal of Nuclear Medicine demonstrates the potential of extending...
recurrent prostate cancer, hormone therapy, radiation therapy, Cedars-Sinai study, New England Journal of Medicine
News | Prostate Cancer | February 03, 2017
Adding hormonal therapy to radiation treatment can significantly improve the average long-term survival of men with...
Overlay Init